Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex

Oncogene

Volumn 33, Issue 41, 2013, Pages 4916-4923

  Liao, J M ^a   Zhou, X ^a   Gatignol, A ^b   Lu, H ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

C MYC; MicroRNA; Ribosomal stress; RPL11; RPL5; TRBP2

Indexed keywords

ARGONAUTE 2 PROTEIN; MESSENGER RNA; MICRORNA; MYC PROTEIN; PROTEIN; PROTEIN P53; PROTEIN TRBP; RIBOSOMAL PROTEIN L11; RIBOSOMAL PROTEIN L5; RIBOSOME PROTEIN; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ARGONAUTE PROTEIN; CULTURE MEDIUM; EIF2C2 PROTEIN, HUMAN; MYC PROTEIN, HUMAN; RIBOSOMAL PROTEIN L5, HUMAN; RNA BINDING PROTEIN; TRANS-ACTIVATION RESPONSIVE RNA-BINDING PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; GENE INACTIVATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN SUBUNIT; RNA DEGRADATION; CELL PROLIFERATION; CULTURE MEDIUM; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; PHARMACOLOGY; RIBOSOME; RNA STABILITY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ARGONAUTE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; RIBOSOMAL PROTEINS; RIBOSOMES; RNA STABILITY; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 84921771048     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.430     Document Type: Article

References (57)

1. Dang C, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15: 6479-6483.
2. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012; 151: 68-79.
3. Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, Berns A. Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 1991; 11: 1176-1179.
4. Soucek L, Whitfield J, Martins C, Finch A, Murphy D, Sodir N et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455: 679-683.
5. Sodir N, Swigart L, Karnezis A, Hanahan D, Evan G, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev 2011; 25: 907-916.
6. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999; 3: 565-577.
7. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297: 102-104.
8. Flores I, Murphy D, Swigart L, Knies U, Evan G. Defining the temporal requirements for Myc in the progression and maintenance of skin neoplAsia. Oncogene 2004; 23: 5923-5930.
9. Felsher D, Bishop J. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4: 199-207.
10. Kim J, Chu J, Shen X, Wang J, Orkin S. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008; 132: 1049-1061.
11. Wright J, Brown S, Cole M. Upregulation of c-MYC in CIS through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol 2010; 30: 1411-1420.
12. Pomerantz M, Ahmadiyeh N, Jia L, Herman P, Verzi M, Doddapaneni H et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 2009; 41: 882-884.
13. Meyer N, Penn L. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8: 976-990.
14. Eilers M, Eisenman R. Myc's broad reach. Genes Dev 2008; 22: 2755-2766.
15. Nesbit C, Tersak J, Prochownik E. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004-3016.
16. Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
17. van Riggelen J, Yetil A, Felsher D. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 2010; 10: 301-309.
18. Gallant P. Myc, cell competition, and compensatory proliferation. Cancer Res 2005; 65: 6485-6487.
19. Dang C. MYC on the path to cancer. Cell 2012; 149: 22-35.
20. Dai M-S, Lu H. Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer. J Cell Biochem 2008; 105: 670-677.
21. Gourse RL, Thurlow DL, Gerbi SA, Zimmermann RA. Specific binding of a prokaryotic ribosomal protein to a eukaryotic ribosomal RNA: implications for evolution and autoregulation. Proc Natl Acad Sci USA 1981; 78: 2722-2726.
22. Dai MS, Arnold H, Sun XX, Sears R, Lu H. Inhibition of c-Myc activity by ribosomal protein L11. EMBO J 2007; 26: 3332-3345.
23. Challagundla KB, Sun XX, Zhang X, DeVine T, Zhang Q, Sears RC et al. Ribosomal protein L11 recruits miR-24/miRISC to repress c-Myc expression in response to ribosomal stress. Mol Cell Biol 2011; 31: 4007-4021.
24. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003; 3: 577-587.
25. Sasaki M, Kawahara K, Nishio M, Mimori K, Kogo R, Hamada K et al. Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nat Med 2011; 17: 944-951.
26. Bhat KP, Itahana K, Jin A, Zhang Y. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J 2004; 23: 2402-2412.
27. Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal- stress checkpoint pathway. Mol Cell Biol 2003; 23: 8902-8912.
28. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 2004; 279: 44475-44482.
29. Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 2004; 24: 7654-7668.
30. Jin A, Itahana K, O'Keefe K, Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 2004; 24: 7669-7680.
31. Zhang Y, Wang J, Yuan Y, Zhang W, Guan W, Wu Z et al. Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26. Nucleic Acids Res 2010; 38: 6544-6554.
32. Yadavilli S, Mayo LD, Higgins M, Lain S, Hegde V, Deutsch WA. Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain. DNA Repair 2009; 8: 1215-1224.
33. Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER et al. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 2007; 26: 5029-5037.
34. Zhu Y, Poyurovsky MV, Li Y, Biderman L, Stahl J, Jacq X et al. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell 2009; 35: 316-326.
35. Zhou X, Hao Q, Liao J, Zhang Q, Lu H. Ribosomal protein S14 unties the MDM2- p53 loop upon ribosomal stress. Oncogene 2013; 32: 388-396.
36. Zhang X, Wang W, Wang H, Wang MH, Xu W, Zhang R. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop. Oncogene 2013; 32: 2782-2791.
37. Xiong X, Zhao Y, He H, Sun Y. Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator. Oncogene 2011; 30: 1798-1811.
38. Sun XX, DeVine T, Challagundla KB, Dai MS. Interplay between ribosomal protein S27a and MDM2 protein in p53 activation in response to ribosomal stress. J Biol Chem 2011; 286: 22730-22741.
39. Horn HF, Vousden KH. Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene 2008; 27: 5774-5784.
40. Miyazaki T, Liu Z, Kawahara A, Minami Y, Yamada K, Tsujimoto Y et al. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 1995; 81: 223-231.
41. Pfeifer-Ohlsson S, Goustin A, Rydnert J, Wahlström T, Bjersing L, Stehelin D et al. Spatial and temporal pattern of cellular myc oncogene expression in developing human placenta: implications for embryonic cell proliferation. Cell 1984; 38: 585-596.
42. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005; 436: 740-744.
43. Haase AD, Jaskiewicz L, Zhang H, Laine S, Sack R, Gatignol A et al. TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. EMBO Reports 2005; 6: 961-967.
44. Koscianska E, Starega-Roslan J, Krzyzosiak WJ. The role of Dicer protein partners in the processing of microRNA precursors. PLoS One 2011; 6: e28548.
45. Ota H, Sakurai M, Gupta R, Valente L, Wulff BE, Ariyoshi K et al. ADAR1 forms a complex with dicer to promote microRNA processing and RNA-induced gene silencing. Cell 2013; 153: 575-589.
46. Zarnack K, Konig J, Tajnik M, Martincorena I, Eustermann S, Stevant I et al. Direct competition between hnRNP C and U2AF65 protects the transcriptome from the exonization of Alu elements. Cell 2013; 152: 453-466.
47. Bursac S, Brdovcak MC, Pfannkuchen M, Orsolic I, Golomb L, Zhu Y et al. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc Natl Acad Sci USA 2012; 109: 20467-20472 .
48. Macias E, Jin A, Deisenroth C, Bhat K, Mao H, Lindstrom MS et al. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell 2010; 18: 231-243.
49. Golomb L, Bublik DR, Wilder S, Nevo R, Kiss V, Grabusic K et al. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell 2012; 45: 222-232.
50. Lu H. A ribosomal tactic to halt cancer. Nat Med 2011; 17: 930-931.
51. Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009; 16: 369-377.
52. Zhang Q, Xiao H, Chai SC, Hoang QQ, Lu H. Hydrophilic residues are crucial for ribosomal protein L11 (RPL11) interaction with zinc finger domain of MDM2 and p53 protein activation. J Biol Chem 2011; 286: 38264-38274.
53. Jin Y, Zeng SX, Sun XX, Lee H, Blattner C, Xiao Z et al. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2. Mol Cell Biol 2008; 28: 1218-1229.
54. Zeng SX, Dai MS, Keller DM, Lu H. SSRP1 functions as a co-activator of the transcriptional activator p63. EMBO J 2002; 21: 5487-5497.
55. Liao JM, Lu H. Autoregulatory suppression of c-Myc by miR-185-3p. J Biol Chem 2011; 286: 33901-33909.
56. Jin Y, Dai MS, Lu SZ, Xu Y, Luo Z, Zhao Y et al. 14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. EMBO J 2006; 25: 1207-1218.
57. Sun XX, Dai MS, Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J Biol Chem 2008; 12387-12392.